New England Journal of Medicine (B+)

2:41 pm Genetic Technologies subsidiary Phenogen Sciences highlights a report in the The New England Journal of Medicine that may regard its BrevaGenplus test (GENE) : According to The New England Journal of Medicine article, there is a reasonably clear distinction between single nucleotide polymorphisms that confer a small increased susceptibility to breast cancer and variants that confer a moderate-to-high susceptibility as identified through sequencing.

BREVAGenplus evaluates a panel of SNPs known to be associated with sporadic breast cancer combined with clinical risk factors to provide a more accurate risk assessment.
.